Information  X 
Enter a valid email address

Nuformix PLC (NFX)

  Print      Mail a friend

Thursday 11 March, 2021

Nuformix PLC

Initiation of research by Allenby Capital

RNS Number : 8718R
Nuformix PLC
11 March 2021
 

REACH: non-regulatory announcement

 

Nuformix plc

("Nuformix", the "Company" or the "Group")

 

Initiation of research by Allenby Capital

 

Cambridge, UK - 11 March 2021:   Nuformix plc (LSE:NFX), a pharmaceutical development company and drug re-purposing specialist, is pleased to announce the initiation of research by Allenby Capital Limited, the Company's broker.

 

The research is available on the Allenby Capital website here:

 

Allenby Capital

 

 

Enquiries:

 

Nuformix plc

Dr Anne Brindley, CEO

Fleur Wood, Investor Relations

 

 

+44 (0)1223 627222

 

 

 

Allenby Capital Limited

Tim Sohal / Matt Butlin (Sales and Corporate Broking)

Nick Athanas / George Payne (Corporate Finance)

 

 

+44 (0)203 328 5656

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.  

 

For more information, please visit www.nuformix.com .

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted companies to distribute media only / non-regulatory news releases into the public domain.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFFFIVFIILIL

a d v e r t i s e m e n t